Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART)

Benjamin Bruno Policicchio1,2*, Paola Sette1,3*, Cuiling Xu1,3, George Haret-Richter1,3, Tammy Dunsmore1,3, Ivona Pandrea1,2,3, Ruy M. Ribeiro4,5, Cristian Apetrei1,2,6*

1 Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 2 Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pennsylvania, United States of America, 3 Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 4 Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America, 5 Laboratorio de Biomatemática, Facultade de Medicina, Universidade de Lisbo, Lisboa, Portugal, 6 Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

* These authors contributed equally to this work.
* apetreic@pitt.edu

Abstract

Two SIVmac251-infected rhesus macaques received tenofovir/emtricitabine with raltegravir intensification. Viral rebound occurred during treatment and sequencing of reverse transcriptase and integrase genes identified multiple resistance mutations. Similar to HIV infection, antiretroviral-resistance mutations may occur in SIV-infected nonhuman primates receiving nonsuppressive ART. As ART administration to nonhuman primates is currently dramatically expanding, fueled by both cure research and the study of HIV-related comorbidities, viral resistance should be factored in the study design and data interpretation.

Introduction

Due to the reverse-transcriptase (RT) infidelity [1], HIV replication is associated with rapid and frequent development of viral mutations, often leading to the emergence of either noninfectious or less fit strains. Antiretroviral (ARV) drug administration selects for specific mutations allowing the virus to evade the drug(s) [2, 3]. Resistance mutations occur more frequently in ARV-treated HIV-infected subjects with incomplete viral suppression. These aspects are largely ignored for SIV-infected nonhuman primates receiving nonsuppressive ART. As ART administration to nonhuman primates is currently dramatically expanding, fueled by both cure research and the study of HIV-related comorbidities, viral resistance should be factored in the study design and data interpretation.
mutations against INTI [8], and monotherapy with NRTIs and INTIs may result in emergence of drug-resistant SIV strains in vivo [9–11].

Here, we report the development of resistance mutations in SIV-infected rhesus macaques (RMs) in a study of INTI intensification following an initial administration of TFV/FTC. The study of SIV resistance to ARVs is relevant, as ARV administration to SIV-infected NHPs is currently dramatically expanding, fueled by both cure research and research targeting HIV-related comorbidities. For these experiments, it is imperative to design appropriate ART regimens ensuring complete and prolonged viral suppression for the assessment of viral reservoirs and for the control of residual inflammation and immune activation. Preventing the emergence of resistance to ARVs is paramount to such studies.

**Materials and methods**

**Ethics statement**

RMs were housed and maintained at the University of Pittsburgh, according to the standards of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) (protocol # 16058287). The animals were cared for according to the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act [12]. Efforts were made to minimize animal suffering: RMs were socially housed together indoors in suspended stainless steel cages, received 12/12 light/dark cycle, were fed twice daily with commercial primate diet, and water was provided ad libitum. A variety of environmental enrichment strategies were employed, including providing toys to manipulate and playing entertainment videos in the animal rooms. The animals were observed twice daily for signs of disease or discomfort, any of which were reported to the veterinary staff for evaluation. For sample collection, animals were euthanized with 10 mg/kg ketamine HCl (Park-Davis, Morris Plains, NJ, USA).

**Animals, infections and treatments**

Two Indian-origin RMs (*Macaca mulatta*) were analyzed in this study. They were intravenously infected with 300 tissue culture doses (TCID50) of SIVmac251 and were closely clinically monitored throughout infection and treatment.

Starting in chronic infection (250 days postinfection), both RMs received tenofovir (TFV) and emtricitabine (FTC) subcutaneously at 20mg/kg and 40mg/kg once daily, respectively. At 4 weeks, this regimen was intensified with orally-administered raltegravir (RAL) (20mg/kg bid). RAL was interrupted after 12 weeks.

**Sampling and sample processing**

Blood was collected from all RMs biweekly, with daily blood sampled upon initiation and interruption of RAL for one week. Within one hour of blood collection, plasma was harvested and peripheral blood mononuclear cells (PBMCs) were separated from the blood using lymphocyte separation media (LSM, MPBio, Solon, OH).

**Plasma viral load quantification**

We monitored the degree of viral suppression by measuring plasma viral loads (pVLs) on all samples collected. pVLs were tested by using qRT-PCR, using the following primers and probe: SIVmac251F: (5’ ~GTC TGC GTC ATC TGG TGC ATT C~3’); SIVmac251R: (5’ ~CAC TAG GTG TCT CTG CAC TAT CTG TTT TG~3’); SIVmac251Probe:
and the conditions described in [4].

Flow cytometry

Whole blood was stained using a two-step TruCount technique to enumerate the absolute levels of CD4+ T cells in the blood, as previously described [13]. The following fluorescently-labeled antibodies were used for staining blood (all antibodies from BD Biosciences, San Jose, CA, USA): CD4 (APC), CD8 (PE-CF594), CD3 (V450), CD45 (PerCP), Ki-67 (PE). Ki-67 was stained by first fixing and permeabilizing cells prior to staining. Flow cytometry acquisitions were performed on an LSR-II flow cytometer (BD Biosciences).

Assessment of the occurrence of resistance mutations

The RT and INT genes of the SIVmac variants circulating in plasma samples collected prior to initiation of ART [0 weeks post-treatment (wpt)], as well as 2, 8, 12 wpt and finally, after cessation of RAL (20 wpt) were sequenced to determine the presence of resistance mutations. The following primers were used for PCR and sequencing: RT outer primers RT3 (5′-GTT GCA TTA AGA GAA ATC TGT GAA AAG ATG G-3′) and RT5 (5′-CCA GGT CTC TCT TTG TGG CAA CTC-3′) and inner primers RT6 (5′-CCA ATC CAT ACA ACA CCC CCA C-3′) and RT7 (5′-CAA CTT CCA TTT TGT CGG CCA C-3′); INT outer primers INTF1 (5′-CAT GGG CAG GTA AAT TCA GAT C-3′) and INTR1 (5′-TAT CCC CTA TTC CTC CCC TTC-3′), and nested primers INTF2 (5′-TAG GGA CTT GGC AAA TGG AYT G-3′) and INTR2 (5′-CTG AAT TTG CTT GTT CCC TGA TTC-3′). These partial gene sequences correspond to specific regions within the RT (566 bp fragment, between N54 and L241) and INT (342 bp fragment, between G59 and S171) known to encompass common resistance mutations. PCR conditions were as follows: RT outer: initial denaturation of 5 minutes at 95˚C; 30 cycles of 1 min at 95˚C, 30 sec at 54˚C, 45 sec at 68˚C; and a final elongation of 5 min at 68˚C. RT inner: initial denaturation of 5 min at 95˚C; 40 cycles of 1 min at 95˚C, 30 sec at 51˚C, 30 sec at 68˚C; and a final elongation of 5 min at 68˚C. INT outer: initial denaturation of 5 min at 95˚C; 30 cycles of 1 min at 95˚C, 30 sec at 50˚C, 30 sec at 68˚C; and a final elongation of 5 min at 68˚C. INT inner: initial denaturation of 5 min at 95˚C; 40 cycles of 1 min at 95˚C, 30 sec at 51˚C, 30 sec at 68˚C; and a final elongation of 5 min at 68˚C. PCR products were gel-purified and submitted to conventional sequencing using the nested primers.

The RT and INT sequences were aligned to the SIVmac251 isolate Mm251 (GenBank: M19499.1) using Sequencher software and the emergence of resistance mutations was assessed based on the Stanford HIV Drug Resistance Database (https://hivdb.stanford.edu).

Nucleotide sequence accession numbers

The nucleotide sequences of the RT and INT from the RMs included in these studies were deposited in the GeneBank (accession numbers: MG686471-MG686486).

Results and discussion

Upon initiation of the TFV/FTC treatment, a ~1.5 log decrease was achieved within the first two weeks in RM130, followed by a 0.7 log rebound in pVL. In RM127, a ~2.5 log decrease in pVL occurred, which was maintained through week 4. Following RAL intensification, at 4 weeks, a ~0.5 log decrease in pVLs occurred in RM130, which was maintained for 2 weeks, but was rapidly followed by a robust pVL rebound throughout the follow-up. Conversely, in
RM127, RAL intensification further suppressed the virus, with pVLs below the limit of detection for at least four weeks. However, at week 8, pVLs rebounded by ~3 log and remained high throughout RAL treatment. Robust pVL rebounds were observed in both animals (~2 log in RM130 and ~1.5 log in RM127) after RAL discontinuation (Fig 1a).

In both animals, CD4⁺ T cells recovered slightly after initiation of NRTIs, with a further recovery following RAL intensification, which was reversed after RAL cessation (Fig 1b), although there was an initial unexplained spike in the number of CD4⁺ T cells. The frequency of CD4⁺ and CD8⁺ T cells expressing Ki-67 remained stable during RAL intensification, and increased after RAL cessation (Fig 1c).

Such patterns of viral replication under ART being suggestive of resistance mutations, we investigated whether this incompletely suppressive treatment resulted in the emergence of drug-resistant strains. Serial sequence analyses demonstrated that major and minor mutations emerged in both genes in both animals (Fig 1a). Thus, sequence analyses showed that, in RM130, major drug resistance mutations occurred at the same time point (12 wpt) in both INT (Q148R) and RT (K65R). Conversely, in RM127, only one major mutation was observed to occur only in the RT at one time point (K65R, 12 wpt), while only one minor mutation was selected in the INT gene at the same time point (I74L, 12 wpt). In humans, occurrence of these mutations was reported to be associated with treatment failure: K65R results in a 3.3–3.6-fold increase in resistance to TFV and Q148R results in a 44-46-fold increase in resistance to RAL [14].

Multiple minor mutations were observed at several time points (2, 8, and 20 wpt) in RM130 RT, with no minor mutations occurring in RM127 (Fig 1). Interestingly, in spite of cessation of RAL treatment, VLs decreased in RM127 at 20 wpt. This may be due to an boost of cell-mediated immune responses against the rebounding resistant virus, as previously reported [11]. Further, the reversion of the K65R mutation to wild type at 20 wpt may explain the observed decrease in VL in RM127.

The mutation M184V/I is a known, frequently-selected major mutation against FTC. The viral strains harboring this mutation have an increased susceptibility to TFV [15, 16]. In our study, none of the sequences from any of the RMs at any time points yielded this major mutation, in spite of the inclusion of FTC in the regimen leading to incomplete SIV suppression. The reasons for the lack of selection of M184V/I may be multiple: (i) first, it is possible that M184V/I never occurred under the combination of TFV and FTC; (ii) second, it is possible that M184V/I occurred, but, as was previously reported [17], it increased viral susceptibility to TFV, thus drastically reducing the fraction of the viruses carrying M184V/I in the virus quasispecies, limiting the probability of detection by Sanger sequencing; (iii) M184V/I occurred but, as was previously reported [18], the fitness of the virus carrying it was drastically altered, resulting again in a frequency of the mutated strains below the limits of detection by Sanger sequencing. Analysis through deep sequencing might thus permit the detection of such minor variants in the quasispecies.

Our analysis documented the accumulation of ART resistance mutations as the cause of treatment failure in two analyzed RMs. To our knowledge, it is very uncommon to find SIV resistance to ARV in vivo in RMs on combination therapy, probably due to the fact that in the past, the duration of treatment was relatively limited, with the treatment given just for the duration of the in vivo experiments and for a much shorter length of time than in HIV-infected subjects [19, 20]. Previous studies reporting that SIV may share similar resistance profiles to HIV and can develop resistance mutations against NRTI or INTI were performed in mono-therapy [6–11].

Clinical trials conducted during the last two decades were plagued by HIV resistance to ART [21], but emergence of viral strains carrying resistance mutations to ARVs tends to be
Fig 1. Administration of nonsuppressive ART to two SIVmac251-infected rhesus macaques resulted in development of resistance mutations and treatment failure. (a) Plasma viral load levels following treatment with TFV/FTC followed by intensification with RAL four weeks later. Reverse transcriptase (RT) and integrase (INT) regions of virus amplified from plasma at select points post-treatment listed in the figure were sequenced to determine the presence or absence of ART-resistance mutations. In the absence of detected resistance mutations at the selected time points, those strains are considered wild type. (b) Peripheral CD4\(^+\) T cell counts during the follow-up. (c) Changes in the levels of circulating CD4\(^+\) and CD8\(^+\) T cell activation during the follow-up, as documented by the frequency of Ki-67 expression.

https://doi.org/10.1371/journal.pone.0190908.g001
ignored when designing and performing NHP studies involving treatments. This is particularly true when the experiments include ARVs administered orally, as in such experimental environments it is very difficult to ensure adherence to treatment in NHPs. The emerging fields of HIV cure and comorbidities combined with new highly-effective suppressive ART regimens for macaques have increased the use of the ART-treated macaque model [22]. However, inappropriate drug regimens or incomplete administrations will not only impact our ability to study the viral reservoirs or HIV-related comorbidities, but will also increase the likelihood of the emergence of SIV resistance to ARVs. The addition of an INTI to the drug regimen effectively reduces viremia [22, 23], suggesting the importance of using first-line ART regimens used in humans for insuring robust and persisted control of the virus. As both cure and comorbidity research require prolonged viral suppression to ART, resistance to ARVs need to be considered as a potentially critical limitation factor in the rapidly emerging field of modeling ART in NHPs, particularly when nonsuppressive ART regimens are used.

**Acknowledgments**

We thank Dr. John Mellors for helpful discussions.

**Author Contributions**

**Conceptualization:** Benjamin Bruno Policicchio, Ivona Pandrea, Ruy M. Ribeiro, Cristian Apetrei.

**Data curation:** Ivona Pandrea, Ruy M. Ribeiro, Cristian Apetrei.

**Formal analysis:** Paola Sette, Cuiling Xu, George Haret-Richter, Ivona Pandrea, Ruy M. Ribeiro, Cristian Apetrei.

**Investigation:** Benjamin Bruno Policicchio, Paola Sette, George Haret-Richter, Tammy Dunsmore.

**Methodology:** Paola Sette, Cuiling Xu, Tammy Dunsmore, Cristian Apetrei.

**Project administration:** Ivona Pandrea.

**Supervision:** Cristian Apetrei.

**Validation:** Benjamin Bruno Policicchio, Paola Sette, Cristian Apetrei.

**Visualization:** Cristian Apetrei.

**Writing – original draft:** Benjamin Bruno Policicchio, Paola Sette.

**Writing – review & editing:** Ivona Pandrea, Ruy M. Ribeiro, Cristian Apetrei.

**References**

1. Svarovskaia ES, Cheslock SR, Zhang WH, Hu WS, Pathak VK. Retroviral mutation rates and reverse transcriptase fidelity. Front Biosci. 2003; 8:d117–34. PMID: 12456349

2. Pennings PS. HIV drug resistance: Problems and perspectives. Infect Dis Rep. 2013; 5(Suppl 1):e5. https://doi.org/10.4081/idr.2013.s1.e5 PMID: 24470969

3. Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiol. 2015; 10(11):1773–82. https://doi.org/10.2217/fmb.15.106 PMID: 26517190

4. Pandrea I, Apetrei C, Dufour J, Dillon N, Barbercheck J, Metzger M, et al. Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts. J Virol. 2006; 80(10):4858–67. https://doi.org/10.1128/JVI.80.10.4858-4867.2006 PMID: 16641277
5. Policicchio BB, Pandrea I, Apetrei C. Animal models for HIV cure research. Front Immunol. 2016; 7:12. https://doi.org/10.3389/fimmu.2016.00012 PMID: 26858716

6. Hassounah SA, Mespelede T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol. 2014; 88(17):9683–92. https://doi.org/10.1128/JVI.00947-14 PMID: 24920794

7. Lloyd SB, Lichtfuss M, Amarasena TH, Alcantara S, De Rose R, Tachedjian G, et al. High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. Virology. 2016; 492:1–10. https://doi.org/10.1016/j.virol.2016.02.008 PMID: 26896929

8. Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, et al. Characterization of the drug resistance profiles of integrase strand transfer inhibitors in simian immunodeficiency virus SIVmac239. J Virol. 2015; 89(23):12002–13. https://doi.org/10.1128/JVI.02131-15 PMID: 26378179

9. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004; 305(5683):528–32. https://doi.org/10.1126/science.1098632 PMID: 15247437

10. Van Rompay KK, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, Matthews TB, et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology. 2007; 4:25. https://doi.org/10.1186/1742-4690-4-25 PMID: 17417971

11. Van Rompay KK, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, et al. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol. 2004; 78(10):5324–37. https://doi.org/10.1128/JVI.78.10.5324-5337.2004 PMID: 15113912

12. National Research Council. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC. 1996.

13. Mandy FF, Nicholson JK, McDougal JS, Cdc. Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003; 52(RR-2):1–13. PMID: 12583540

14. Andreattta KN, Miller MD, White KL. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions. Antimicrob Agents Chemother. 2016; 60(2):757–65. https://doi.org/10.1128/AAC.02096-15 PMID: 26574015

15. McColl DJ, Margot N, Chen SS, Harris J, Borroto-Esoda K, Miller MD. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naive subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. HIV Clin Trials. 2011; 12(2):61–70. https://doi.org/10.1089/hct.2011.0111

16. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr. 2009; 52(2):209–21. https://doi.org/10.1097/QAI.0b013e3181b05f7c PMID: 19643834

17. Murry JP, Higgins J, Matthews TB, Huang YY, Van Rompay KK, Pedersen NC, et al. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol. 2003; 77(2):1120–30. https://doi.org/10.1128/JVI.77.2.1120-1130.2003 PMID: 12502828

18. Van Rompay KK, Matthews TB, Higgins J, Canfield DR, Tarara RP, Wainberg MA, et al. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol. 2002; 76(12):6083–92. https://doi.org/10.1128/JVI.76.12.6083-6092.2002 PMID: 12021341

19. Gordon SN, Dunham RM, Engram JC, Estes J, Wang Z, Klatt NR, et al. Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol. 2008; 82(7):3725–35. https://doi.org/10.1128/JVI.02408-07 PMID: 18216113

20. Pandrea I, Ribeiro RM, Gautham R, Gauflin T, Pattison M, Barnes M, et al. Simian Immunodeficiency Virus SIVagm Dynamics in African Green Monkeys. Journal of Virology. 2008; 82(7):3713–24. https://doi.org/10.1128/JVI.02402-07 PMID: 18216122

21. Collins SE, Grant PM, Shafer RW. Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients. Drugs. 2016; 76(1):75–98. https://doi.org/10.1007/s40265-015-0515-6 PMID: 26677129

22. Del Prete GQ, Smedley J, Macallister R, Jones GS, Li B, Hattersley J, et al. Short Communication: Comparative evaluation of coformulated injectable combination antiretroviral therapy regimens in ART failure in rhesus macaques due to SIV resistance.
simian immunodeficiency virus-infected rhesus macaques. AIDS Res Hum Retroviruses. 2016; 32 (2):163–8. https://doi.org/10.1089/AID.2015.0130 PMID: 26150024

23. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, et al. Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques. Science. 2004; 305(5683):528–32. https://doi.org/10.1126/science.1098632 PMID: 15247437